Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) EPS (Basic) : $2.84 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals EPS (Basic)?

Amphastar Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $0.75. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.84.

Amphastar Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2023 was $0.68. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.58.

Amphastar Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $0.88. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 3.18.

During the past 12 months, Amphastar Pharmaceuticals's average EPS without NRIGrowth Rate was 49.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 342.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Amphastar Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 342.50% per year. The lowest was -48.00% per year. And the median was 3.60% per year.

Amphastar Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Amphastar Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals EPS (Basic) Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

1.04

0.03

1.30

1.88

2.85

Amphastar Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															0.70	0.54	0.54	1.01	0.75

Amphastar Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Amphastar Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(137.545	-	0)	/	48.265
	=	2.85

Amphastar Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(36.167	-	0)	/	47.956
	=	0.75

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.84

Amphastar Pharmaceuticals (NAS:AMPH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Amphastar Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

29A:Germany 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Executives

Mary Z. Luo	director, 10 percent owner, officer: COO and Chief Scientist	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou	officer: EVP, Production	C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins	director
William J Peters	officer: CFO, SVP & Treasurer	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi	officer: SVP Corp Admin Center	C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff	director
Gayle Deflin	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst	officer: EVP, QA & Regulatory Affairs	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee	director	13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang	director, 10 percent owner, officer: CEO & Chief Scientific Officer	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris	director	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell	director, officer: President	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc.	10 percent owner	13760 MAGNOLIA AVENUE, CHINO CA 91710